Founders tackling vital therapeutic challenges
We have built a portfolio of companies at the forefront of Life Sciences innovation. It features leading-edge ventures with transformative potential across various therapeutic modalities and disease areas, and driven by ambitious entrepreneurs who share our ambition to shape the future of healthcare.
Disruptive companies improving patients’ lives
“We deeply appreciate the trust placed in us by the Criteria Bio Ventures team, who recognized early on the game changing potential of our program. CBV was the cornerstone investor to secure a Series A financing with an international syndicate for the next clinical phase of the company.”
Ann Meulemans, PhD, CEO of Aboleris Pharma
“Together with Caixa Capital Risc we have brought our science and drug candidates from academia to the clinic to become a leading company in calcification disorders. CCR’s unwavering support has been instrumental at every phase, propelling us forward in a journey that culminated in a successful transaction with Vifor.”
Joan Perelló, PhD, CEO of Sanifit Therapeutics
“We dared to dream big in our pursuit of changing cancer treatment with Caixa Capital Risc as our earlier investor. Now, our clinical assets found new homes with industry leaders Boehringer Ingelheim and AstraZeneca to bring these therapies to patients.”
Judit Anido, PhD, VP Operations and Corporate Affairs at Northern Biologics, and co-founder and CEO of Mosaic Biomedicals
“It has been a genuine delight to advance Minoryx in collaboration with Caixa Capital Risc, who have consistently supported the project since its inception.”
Marc Martinell, PhD, CEO of Minoryx
